Back to Newsroom

Migraine drug shows positive results, says Alder Biopharma

Bothell-based Alder Biopharmaceuticals is one step closer to commercializing a treatment for migraine prevention, according to results of a Phase 2 trial being published Monday in the journal Lancet Neurology.

By Coral Garnick

After three years of development, Bothell-based Alder Biopharmaceuticals is one step closer to commercializing a treatment for migraine prevention, according to results of a Phase 2 trial being published Monday in the journal Lancet Neurology.

Click here to read the full article